Palatin Technologies, Inc.
- PTN
- NASDAQ
- Biotechnology
- Melanocortin Receptor Drugs
- Biopharmaceutical R&D
$5.93
Today −1.50%Quote Oct 19, 2026, 07:39 PM UTC
−42.28%over the last month
Max drawdown −44.6%From 1-month high −44.6%3 months −29.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Palatin Technologies
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
25
Founded
1986
Market value
$10.6M
Quote Oct 19
Analyst target
$47.50
+701.0% from here
Floor
$5.50
7.3% below price
Resistance
$6.53
10.1% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about PTNPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free